

# Perioperative supplementation with bifidobacteria improves postoperative nutritional recovery, inflammatory response, and fecal microbiota in patients undergoing colorectal surgery: a prospective, randomized clinical trial

Minoru MIZUTA<sup>1</sup>, Izuru ENDO<sup>1</sup>, Sumiharu YAMAMOTO<sup>1</sup>, Hidetoshi INOKAWA<sup>1</sup>, Masatoshi KUBO<sup>1</sup>, Tetsunobu UDAKA<sup>1</sup>, Osanori SOGABE<sup>1</sup>, Hiroya MAEDA<sup>1</sup>, Kazutoyo SHIRAKAWA<sup>1</sup>, Eriko OKAZAKI<sup>2</sup>, Toshitaka ODAMAKI<sup>3</sup>, Fumiaki ABE<sup>4</sup> and Jin-zhong XIAO<sup>3\*</sup>

<sup>1</sup> Mitoyo General Hospital, Takamatsu, Kagawa 769-1695, Japan

<sup>2</sup> Clinico Co., Ltd., Tokyo 153-0063, Japan

<sup>3</sup> Next Generation Science Institute, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama City, Kanagawa 252-8583, Japan

<sup>4</sup> Food Ingredients and Technology Institute, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama City, Kanagawa 252-8583, Japan

Received August 10, 2015; Accepted November 9, 2015; Published online in J-STAGE December 9, 2015

The use of probiotics has been widely documented to benefit human health, but their clinical value in surgical patients remains unclear. The present study investigated the effect of perioperative oral administration of probiotic bifidobacteria to patients undergoing colorectal surgery. Sixty patients undergoing colorectal resection were randomized to two groups prior to resection. One group (n=31) received a probiotic supplement, *Bifidobacterium longum* BB536, preoperatively for 7–14 days and postoperatively for 14 days, while the other group (n=29) received no intervention as a control. The occurrences of postoperative infectious complications were recorded. Blood and fecal samples were collected before and after surgery. No significant difference was found in the incidence of postoperative infectious complications and duration of hospital stay between the two groups. In comparison to the control group, the probiotic group tended to have higher postoperative levels of erythrocytes, hemoglobin, lymphocytes, total protein, and albumin and lower levels of high sensitive C-reactive proteins. Postoperatively, the proportions of fecal bacteria changed significantly; Actinobacteria increased in the probiotic group, Bacteroidetes and Proteobacteria increased in the control group, and Firmicutes decreased in both groups. Significant correlations were found between the proportions of fecal bacteria and blood parameters; Actinobacteria correlated negatively with blood inflammatory parameters, while Bacteroidetes and Proteobacteria correlated positively with blood inflammatory parameters. In the subgroup of patients who received preoperative chemoradiotherapy treatment, the duration of hospital stay was significantly shortened upon probiotic intervention. These results suggest that perioperative oral administration of bifidobacteria may contribute to a balanced intestinal microbiota and attenuated postoperative inflammatory responses, which may subsequently promote a healthy recovery after colorectal resection.

**Key words:** probiotics, *Bifidobacterium*, colorectal surgery, postoperative complications, microbiota, nutrition, inflammation

## INTRODUCTION

Probiotics are defined as “live microorganisms which when administered in adequate amounts confer a health benefit on the host” [1]. Bifidobacteria and lactic acid bacteria are the main genera of probiotic microorganisms. Probiotics are widely documented for their roles in prevention and treatment of diseases, primarily via improving the intestinal environment and enhancing host defense functions [2, 3]. Clinical trials have illustrated that

\*Corresponding author. Mailing address: Jin-zhong Xiao, Next Generation Science Institute, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama City, Kanagawa 252-8583, Japan. Phone: +81-46-252-3074, Fax: +81-46-252-3077. E-mail: j\_xiao@morinagamilk.co.jp

©2016 BMFH Press

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <<http://creativecommons.org/licenses/by-nc-nd/4.0/>>.

prophylactic administration of probiotics, and in some cases together with prebiotics (as synbiotics), to patients undergoing abdominal surgery reduced postoperative infections [4–8]. Systematic reviews and meta-analyses showed that the use of pro-/synbiotics has positively affected clinical outcomes after abdominal surgery [9, 10]. However, another study demonstrated that the effect of prophylactic administration of probiotics to patients undergoing different types of gastrointestinal surgeries was insignificant [11]. The effects of pro-/synbiotics on postoperative infections in colorectal cancer patients remain controversial, and studies involving specific strains of probiotics for specific groups of patients are needed to better justify their efficacy.

The present study investigated the effect of a probiotic strain, *Bifidobacterium longum* BB536, which has been reported to have various physiological effects [12, 13], on immune functions, systemic inflammatory responses, and postoperative infectious complications in patients undergoing colorectal surgery. Fecal microbial profiling was also performed to better understand the possible roles of microbiota on health conditions of patients and to justify the positive outcomes of probiotic intervention.

## MATERIALS AND METHODS

### Study design and participants

Patients who had colorectal cancer at 20–85 years of age and were scheduled to undergo colorectal cancer resection at Mitoyo General Hospital between October 2008 and December 2012 were enrolled in this study. The exclusion criteria were severe diseases of the liver, kidney, heart, and lung and the presence of a food allergy. Patients with bowel obstruction were also excluded. Written informed consent for participation was obtained from each patient before enrollment. All study protocols were reviewed and approved by the Local Ethics Committee of Mitoyo General Hospital, Takamatsu, Japan, and complied with the Helsinki Declaration as revised in 1983. A flow diagram of participants is shown in Fig. 1.

This was a randomized, single-center, single-blinded trial. Physicians involved with the diagnosis of infections and researchers performing the statistical analyses were not involved in the randomization process. The subjects were randomized before surgery to either the probiotic group or control group using a computer-generated permuted-block randomization. Subjects in the probiotic group received a sachet containing 2 g of *B. longum* BB536 powder (approximately  $5 \times 10^{10}$  colony-forming units/2 g) daily for 7–14 days preoperatively and 14 days




Fig. 1. Flow diagram for the study.

postoperatively (starting one day after surgery). The subjects were advised to ingest this powder by drinking it with milk or water. Subjects who did not receive the intervention were used as a control group.

### Clinical observation and blood analyses

All patients started fasting one day before surgery and underwent preoperative bowel preparation by orally taking an electrolyte-compounding agent (2 L, Niflec, Ajinomoto Pharmaceuticals). All patients received antibiotic prophylaxis (cefmetazole) as a single intravenous drip infusion on the day of surgery and one day after surgery. An additional postoperative antibiotic was prescribed when recommended by the physicians who diagnosed the patients. Detailed daily records of each patient's postoperative course were kept, and infectious complications were recorded for 14 days after surgery in accordance with the Guideline for the Prevention of Surgical Site Infection (1999) [14].

Blood samples were collected before and after surgery (days: -14, 1, 4, 7, and 14) to assess biomarkers related to the health condition of the patients, with the exception of natural killer (NK) cell activity and interleukin (IL)-6, which were assessed on days -14, 1, and 7. NK cell activity (%) was measured by a  $^{51}\text{Cr}$ -release assay [15]. All measurements were performed by SRL, Inc. (Tokyo, Japan).

### Analysis of fecal microbiota

Fecal samples were collected from each subject before probiotic ingestion at prior to surgery, and 1 week after surgery using a sampling kit (Techno Suruga Laboratory Co., Ltd., Shizuoka, Japan), which enabled

quick stabilization of DNA and processing of samples at normal room temperature. Six patients failed to provide samples before or after surgery; a total of 54 full sets of samples were collected (28 in the probiotic group and 26 in the control group).

DNA was extracted from the fecal samples as previously described [16] with some modifications. Fifty microliters of 10% sodium dodecyl sulfate, 500  $\mu$ l of phenol-chloroform, and 300 mg of glass beads (diameter, 0.1 mm) were added to 450  $\mu$ l of fecal suspension. The mixture was vigorously vortexed at 2,700 rpm for 3 minutes at 4°C using a Multi-beads shaker (MBS01(S), Yasui Kikai Corporation, Osaka, Japan). After centrifugation at 14,000 $\times$ g for 5 min, 400  $\mu$ l of supernatant was extracted with phenol-chloroform, and 250  $\mu$ l of the supernatant was precipitated with isopropanol. Inhibitors were removed using a High Pure PCR Template Preparation Kit (Roche). The purified DNA was suspended in 200  $\mu$ l of Tris-EDTA buffer (pH 8.0).

The V3-V4 region of bacterial 16S rRNA genes was amplified by PCR with a TaKaRa Ex Taq HS kit (TaKaRa Bio, Shiga, Japan) and the primer set of Tru357F (5'-CGCTCTTCCGATCTCTGTACGGRAGGCAGCAG-3') and Tru806R (5'-CGCTCTTCCGATCTGACGGACTACHVGGGTWTCTAAT-3'). DNA was amplified according to the following program: preheating at 94°C for 3 min; 25 cycles of denaturation at 94°C for 30 sec, annealing at 50°C for 30 sec, and extension at 72°C for 30 sec; and a final terminal extension at 72°C for 10 min. Upon checking the size and the quantity of the amplified DNA using a QIAxcel system (Qiagen, Valencia, CA, USA), 1  $\mu$ l of the PCR products were amplified with a 2nd primer set, adapted for the Illumina MiSeq. DNA was amplified using the same program as described above, except that a 15 amplification cycles were used instead of 25. After checking the size and the quantity of the 2nd set of amplified DNA products using the QIAxcel system, the products were purified using a QIAquick 96 PCR Purification Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. The purified products were quantified using a QuantiT PicoGreen dsDNA Assay kit (Life Technologies, Carlsbad, CA, USA). Subsequently, equal amounts of the amplicons from different samples were pooled, and primer-dimers were removed by gel extraction with a QIAquick PCR Purification Kit. The pooled libraries were sequenced using an Illumina MiSeq instrument with a MiSeq v2 Reagent kit.

The Illumina paired-end reads that passed the quality

filters were combined by the fastq-join script in EA-Utils (ver. 1.1.2-537) [17]. The sequences were then analyzed using the QIIME software package version 1.6.0 [18, 19] (<http://quime.org/>). Potential chimeric sequences were removed using UCHIME, assigned to operational taxonomic units (OTUs) using open-reference OTU picking [20] with a 97% threshold of pairwise identity, and then classified taxonomically using the Greengenes reference database ([http://greengenes.secondgenome.com/downloads/database/12\\_10](http://greengenes.secondgenome.com/downloads/database/12_10)) and a confidence threshold of 60% [21]. As a result, 1,363,590 sequences were assigned to 108 samples, in which the average  $\pm$  standard deviation of the read number per sample was 12,625  $\pm$  3,370. UniFrac distances were calculated from the Illumina V3-4 16S rRNA gene dataset.

#### *Statistical analyses*

Postoperative infectious complication was predetermined as the primary efficacy variable. The secondary variables were as follows: additional postoperative antibiotic treatment, hospital stay, and changes in blood parameters and the microbiota. Regarding sample size, a minimum of 60 subjects were required to demonstrate a reduction in postoperative infectious complications from 40% to 15% at a 5% significant level with 80% power, similar to that seen in another study [22].

Results of blood parameters are expressed as the mean  $\pm$  SD or SE. Statistical analyses were performed using the paired and unpaired Student's t-test for continuous variables and Fisher's exact test for categorical variables in comparison between the control and probiotic groups. Variables that did not follow a normal distribution were analyzed after natural log transformation. The data for the microbiota were expressed as the median and interquartile range (IQR) of the proportion of each bacterial category in the microbiota, and the within-group difference and between-group difference at each time point were analyzed using the Wilcoxon signed-rank test and Mann-Whitney U-test, respectively. Statistical significance was determined at  $p < 0.05$ .

## RESULTS

#### *Demographics of patients and clinical observation*

A total of 60 patients, 31 in the probiotic group and 29 in the control group, were enrolled. The baseline characteristics of the probiotic and control groups are shown in Table 1. No significant differences in sex, age, BMI, types of surgery, and length of operation were found between the two groups (Table 1). In addition,

Table 1. Background characteristics for all patients and those patients who received preoperative chemoradiotherapy (CRT)

	All patients <sup>†</sup>		CRT patients <sup>†</sup>	
	Control (n=29)	Probiotic (n=31)	Control (n=7)	Probiotic (n=8)
Gender (Male/Female)	15/14	20/11	6/1	7/1
Age (years)	71.2 ± 9.5	68.9 ± 10.4	71.3 ± 8.8	65.9 ± 8.2
Body mass index (BMI)	24.1 ± 3.4	22.4 ± 3.7	24.0 ± 2.6	21.3 ± 3
Preoperative chemoradiotherapy (CRT)	7 (24.1%)	8 (25.8%)	-	-
Preoperative diabetes	6 (20.7%)	6 (19.4%)	0	0
Preoperative complication	5 (17.2%)	7 (22.6%)	2 (28.6%)	2 (25.0%)
Operation time (min)	230.0 ± 84.4	218.9 ± 88.7	305.9 ± 110.4	281.0 ± 121.3
Types of surgery				
Colon	13	11	0	0
Rectum	12	19	6	8
Others	4 <sup>‡</sup>	0	1 <sup>§</sup>	0
Blood parameters before surgery (D-14)				
White blood cells (/μl)	5,603 ± 1,910	5,446 ± 1,559	4,570 ± 968	4,950 ± 1,331
Erythrocytes (10 <sup>4</sup> /μl)	433 ± 46	417 ± 42	438.4 ± 51.8	413.9 ± 32.2
Hemoglobin (g/dl)	12.3 ± 1.8	12.4 ± 2.1	13.2 ± 1.8	1 ± 1.4
Lymphocytes (%)	27.8 ± 8.5	24.4 ± 10.3	18.3 ± 4.2	27.3 ± 9.2**
Platelet (10 <sup>4</sup> /μl)	22.8 ± 9.5	26.6 ± 10.2	20.0 ± 6.6	19.6 ± 9.1
Total protein (g/dl)	7.0 ± 0.6	6.8 ± 0.7	6.8 ± 0.7	6.4 ± 0.9
Albumin (g/dl)	4.0 ± 0.4	3.8 ± 0.6	4.0 ± 0.4	3.5 ± 0.7*
hCRP (mg/dl)	0.5 ± 1.5	0.5 ± 0.6	0.2 ± 0.1	0.4 ± 0.3
IL-6 (pg/ml)	6.0 ± 9.1	6.6 ± 10.2	3.5 ± 1.7	11.1 ± 18.8
NK cell activity (%)	40.3 ± 18.1	43.8 ± 13.6	40.0 ± 14.4	42.6 ± 15.4

<sup>†</sup>Groups were compared using Student's t-test for continuous variables and Fisher's exact test for categorical variables. \*p<0.05, \*\*p<0.01. <sup>‡</sup>Anal canal cancer (n=1), postoperative local recurrence of rectum cancer (n=1), rectovaginal fistula (n=1), colostomy (n=1).

<sup>§</sup>Anal canal cancer.

no significant differences were found in the numbers of subjects with preoperative diabetes and preoperative complications. The probiotic group included 11 colon and 19 rectal cancer patients, whereas the control group included 12 patients with colon cancer, 13 patients with rectal cancer, 1 patients with anal canal cancer, 1 patients with local postoperative recurrence of rectal cancer, 1 patients with rectovaginal fistula, and 1 colostomy patient. The study groups did not differ significantly in preoperative values of blood parameters.

Among the patients with rectal and anal canal cancer, 8 in the probiotic group and 7 in the control group received preoperative chemoradiotherapy (CRT). The CRT was performed by oral administration of 5-FU/1-LV for 7 to 9 weeks accompanied by irradiation treatment (3 Gy per day, up to a total of 45 Gy). Surgery was performed 6 to 8 weeks after the CRT. The study groups did not differ significantly in preoperative values of blood parameters with the exception of lymphocytes and albumin. Among the CRT patients, a significantly higher level of lymphocytes (p<0.01) and lower level of albumin (p<0.05) were observed in the probiotic group compared with the control group (Table 1).

The rates of postoperative infections did not differ significantly between the probiotic and control groups (p>0.1); 16.1% and 24.1% for superficial surgical site infections (SSI), 6.5% and 10.3% for deep SSI, and 9.7% and 17.2% for anastomotic leakage, respectively, for the probiotic and control groups. Insignificant differences (p>0.1) were also observed in the frequency of additional postoperative antibiotic treatment and duration of hospital stay between the two groups (Table 2).

The occurrences of postoperative infections in patients who received preoperative CRT treatment were higher than those without CRT treatment (Table 2). Four patients in the control group but none in the probiotic group experienced postoperative anastomotic leakage (p=0.10, probiotic vs control). In addition, the duration of hospital stay was significantly shortened in the probiotic group (39.6 ± 15.6 days, p=0.03) compared with the control group (21.6 ± 11.7 days).

#### Changes in blood parameters

The blood parameters changed significantly after surgery in both the control and the probiotic groups (Fig. 2). There were significant increases in white blood

Table 2. Clinical observations for all patients and those patients who received preoperative chemoradiotherapy (CRT)

	All patients <sup>†</sup>		CRT patients <sup>†</sup>	
	Control (n=29)	Probiotic (n=31)	Control (n=7)	Probiotic (n=8)
Hospital stay (day)	23.0 ± 13.8	21.4 ± 10.1	39.6 ± 15.6	21.6 ± 11.7 *
Surficial infection	7 (24.1%)	5 (16.1%)	4 (57.1%)	3 (37.5%)
Deep infection	3 (10.3%)	2 (6.5%)	3 (42.9%)	2 (25.0%)
Anastomotic leak	5 (17.2%)	3 (9.7%)	4 (57.1%)	0
Additional antibiotic treatment	7 (24.1%)	8 (25.8%)	5 (71.4%)	3 (37.5%)

<sup>†</sup>Groups were compared using Student's t-test for continuous variables and Fisher's exact test for categorical variables. \*p<0.05.

cells and high-sensitive C-reactive protein (hCRP) and significant decreases in erythrocytes, hemoglobin, lymphocytes, total protein, albumin, and NK cell activity after surgery (D1) in the control and probiotic groups (Fig. 2). Significant between-group differences were found in the changes from preoperative levels (D–14) of erythrocytes (D14), total protein (D1), and albumin (D1 and D7). Tendencies for differences (p<0.1) were also found in the changes from baseline values (D–14) of hemoglobin (D14), lymphocytes (D1), and hCRP (D14) between the two groups (Fig. 2).

Among those patients who received CRT treatment, similar within-group changes and between-group differences as found in the whole groups were observed (Fig. 3). In particular, the levels of hCRP remained high at two weeks after surgery in the control group, but declined to near preoperative levels in the probiotic group (Fig. 3). In addition, 7 days after surgery, NK cell activity recovered to near preoperative levels in the probiotic group, but remained low in the control group (Fig. 3). Significant between-group differences were found in the changes from preoperative levels (D–14) of white blood cells (D14), erythrocytes (D14), and hCRP (D7 and D14). Tendencies of differences (p<0.1) were also found in the changes from baseline values (D–14) of white blood cells (D1), hemoglobin (D14), and total protein (D14) between the two groups (Fig. 3).

#### *Changes in fecal microbiota*

High-throughput sequencing analysis of the fecal microbiota at the phylum level indicated significant postoperative increases in the proportion of Bacteroidetes and Proteobacteria, but significant decreases in those of Firmicutes and unclassified bacterial groups in the control group (Table 3). On the other hand, the proportion of Actinobacteria increased and proportion of Firmicutes decreased significantly in the probiotic group. The proportions of these bacterial groups did not differ significantly between the two groups at before or after surgery (Table 3).

#### *Correlation between compositions of fecal microbiota with blood parameters*

Taking into consideration the whole samples collected preoperatively and postoperatively, analysis revealed the following correlations between the proportions of bacterial groups with blood parameters: 1) Actinobacteria significantly correlated positively with erythrocytes, hemoglobin, albumin, and NK cell activity; 2) Firmicutes significantly correlated positively with lymphocytes, total protein, and albumin, but negatively with white blood cells, hCRP, and IL-6; 3) the proportions of Bacteroidetes significantly correlated negatively with total protein and albumin but positively with hCRP and IL-6; and 4) the proportions of Proteobacteria significantly correlated negatively with erythrocytes, hemoglobin, lymphocytes, total protein, and albumin but positively with white blood cells, hCRP and IL-6 (Table 4). The correlations associated with Actinobacteria were observed in samples collected both preoperatively or postoperatively; however, the correlations associated with Proteobacteria were not observed in samples collected preoperatively (Table 4).

## DISCUSSION

Postoperative infections remain significant risk factors for patients undergoing surgery for cancers, such as colorectal cancer and biliary cancer, and are often indicators of postoperative health and recovery. Zhang, Liu and colleagues [22–24] evaluated the effects of administering perioperative probiotic supplements containing *L. plantarum*, *L. acidophilus*, and *B. longum* to patients undergoing colorectal resection. The probiotic group recovered postoperative peristalsis more rapidly, accompanied by lower incidences of diarrhea and infectious-related complications [22].

In the present study, although the incidence of SSI was higher in the control group than in the probiotic group, the difference was not significant. However, among the patients who received preoperative CRT, the duration




Fig. 2. Changes in blood parameters during the trial period for patients who underwent colorectal surgery.

Changes in values, compared with D-14, are shown as means  $\pm$  SE.  $\circ$ , control group;  $\bullet$ , probiotic group. \* $p$ <0.05, \*\* $p$ <0.01, paired t-test with Bonferroni correction for within-group differences from baseline (D-14). † $p$ <0.1, ‡ $p$ <0.05; Student's t-test for between-group differences at each time point. (A) white blood cell; (B) erythrocytes; (C) hemoglobin; (D) lymphocytes; (E) platelets; (F) total protein; (G) albumin; (H) high sensitive C-reactive protein; (I) interleukin-6; (J) natural killer cell activity.




Fig. 3. Changes in blood parameters during the trial period among patients who received preoperative chemoradiotherapy.

Changes in values, compared with D-14, are shown as means  $\pm$  SE.  $\circ$ , control group;  $\bullet$ , probiotic group. \* $p$ <0.05, \*\* $p$ <0.01, paired t-test with Bonferroni correction for within-group differences from baseline (D-14). † $p$ <0.1, ‡ $p$ <0.05, # $p$ <0.01, Student's t-test for between-group differences at each time point. (A) white blood cell; (B) erythrocytes; (C) hemoglobin; (D) lymphocytes; (E) platelets; (F) total protein; (G) albumin; (H) high-sensitive C-reactive protein; (I) interleukin-6; (J) natural killer cell activity.

of postoperative hospital stay differed significantly between the two groups. CRT, which is usually applied to patients with severe case, often disrupts the colonization of indigenous microbiota and subsequently affects gut immunity [25, 26]. We observed a higher incidence of

SSI in the CRT patients compared with those without CRT treatment (Table 1). The patients in the control group also had increased levels of hCRP and IL-6, accompanied by decreased levels of NK cell activity two weeks after surgery (Fig. 3). High postoperative levels

Table 3. The proportions of bacterial phyla in the fecal microbiota

Category at phylum level	Control group				BB536 group			
	Before surgery		After surgery		Before surgery		After surgery	
	median (%)	IQR (%)	median (%)	IQR (%)	median (%)	IQR (%)	median (%)	IQR (%)
Actinobacteria	1.95	0.32–4.89	0.63	0.21–2.60	0.70	0.24–1.90	1.71	0.36–3.09*
Bacteroidetes	24.52	18.32–32.01	32.80	27.17–40.60*	24.72	18.88–32.89	29.56	24.76–32.87
Firmicutes	66.57	57.18–75.96	56.82	46.77–64.24*	62.31	52.34–72.98	56.51	48.46–64.15*
Fusobacteria	0.23	0.08–1.37	0.25	0.07–3.76	0.18	0.10–2.09	0.69	0.09–2.75
Proteobacteria	1.74	1.50–2.16	3.54	2.90–5.84*	2.05	1.54–5.06	3.43	2.27–9.75
Unclassified	0.50	0.37–0.55	0.37	0.26–0.51*	0.33	0.25–0.51	0.32	0.21–0.46

The data for the microbiota were expressed as the median and interquartile range (IQR) of the proportion of each bacterial category. \*p<0.05, intra-group difference.

Table 4. Correlations between blood biochemical parameters and the composition of fecal microbiota of all patients

Blood parameters	Data analysis	Spearman's correlation				
		Actinobacteria	Bacteroidetes	Firmicutes	Proteobacteria	Unclassified
White blood cells	Before+after	-0.062	0.127	-0.246*	0.205*	-0.114
	Before	-0.183	-0.013	-0.016	0.037	-0.078
	After	0.017	0.048	-0.287*	0.099	0.02
Erythrocytes	Before+after	0.211*	-0.095	0.046	-0.308**	0.06
	Before	0.204	0.061	-0.206	-0.132	0.105
	After	0.312*	0.082	-0.102	-0.165	-0.158
Hemoglobin	Before+after	0.361**	-0.052	0.032	-0.241*	0.138
	Before	0.301*	0.054	-0.11	-0.045	0.153
	After	0.472**	0.074	-0.141	-0.196	-0.013
Lymphocytes	Before+after	0.131	-0.152	0.317**	-0.322**	0.189†
	Before	0.234†	-0.054	0.037	0.025	0.186
	After	0.035	-0.016	0.366**	-0.282*	0.034
Total protein	Before+after	0.099	-0.267**	0.311**	-0.373**	0.039
	Before	0.031	-0.131	0.134	-0.094	-0.13
	After	0.228	-0.144	0.122	-0.252†	-0.074
Albumin	Before+after	0.242*	-0.240*	0.311**	-0.391**	0.171†
	Before	0.383*	0.083	-0.056	-0.158	0.034
	After	0.294*	-0.194	0.300*	-0.297*	-0.022
hCRP	Before+after	-0.163†	0.222*	-0.263**	0.398**	-0.277**
	Before	-0.179	-0.02	0.112	0.159	-0.227†
	After	-0.247†	0.043	-0.203	0.154	-0.173
IL-6	Before+after	-0.231*	0.199**	-0.204**	0.327***	-0.236*
	Before	-0.321*	0.005	-0.136	0.185	-0.13
	After	-0.348*	0.004	-0.184	0.155	-0.074
NK cell activity	Before+after	0.231*	0.026	0.02	0.049	0.034
	Before	0.249†	0.052	0.012	0.139	0.122
	After	0.271†	0.002	0.047	0.047	0.157

Analysis was based on data of blood parameters and the composition of fecal microbiota obtained at before and/or after surgery of all patients. Blood parameters employed for before and after operation were those obtained at D-14 and D7, respectively. †p<0.1, \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, Spearman's correlation analysis.

of CRP are associated with bacterial translocation and prolonged hospitalization and are often critical indicators of post-operative infections [22]. Our results showed significantly earlier postoperative recovery of serum levels of hCRP and NK cell activity in the probiotic

group compared with the control group among CRT patients. This is in agreement with previous reports that demonstrated the potential of *B. longum* BB536 in suppressing inflammatory reactions and maintaining innate immune responses [13, 27].

Surgery led to significant declines in the levels of erythrocytes, hemoglobin, total protein and albumin, however, an improvement in postoperative recovery of hematological and nutritional parameters was observed in the probiotic group. To our knowledge, this is the first report on the possible effects of perioperative probiotic intervention on postoperative hematological and nutritional parameters of patients undergoing colectomy for cancer. The exact mechanisms of bifidobacteria in improving hematological and nutritional parameters remain unclear. However, several possibilities have been suggested: (1) increased mineral solubility through the production of short-chain fatty acids; (2) production of a phytase that reduces phytate as an antinutrient that leads to mineral unavailability; (3) reducing inflammation, which negatively impacts mineral uptake and nutritional status; and (4) hydrolysis of glycoside bonds of food in the intestines [28]. In addition, some bifidobacteria, including *B. longum* BB536, have been reported to have a high potential for producing folate [29, 30]. Folate is crucial for its roles in essential functions of cell metabolism, such as DNA replication, repair, and methylation and synthesis of nucleotides, vitamins, and some amino acids, and has been known to promote the generation of erythrocytes [31, 32]. In addition, *B. longum* BB536 has also been demonstrated to possess anti-inflammatory effects [27]. We postulate that the improved postoperative nutritional status observed in the present study was attributed to the anti-inflammatory effects and the production of folate and phytase in the intestine by *B. longum* BB536. However, further study is needed to elucidate the details of these mechanisms.

Several studies have demonstrated the effects of perioperative probiotic supplementation on the gastrointestinal microbiota [5, 6, 8, 22]. We observed significant changes at the phylum level in the fecal microbiota 1 to 2 weeks after surgery (Table 3); Firmicutes increased in both groups, Proteobacteria and Bacteroidetes increased in the control group but not in the probiotic group, and Actinobacteria increased in the probiotic group but not in the control group. In addition, we found some feeble but significant correlations between the proportions of the microbiota and blood parameters. The proportions of Proteobacteria and Bacteroidetes positively correlated with the levels of inflammatory parameters (CRP, IL-6, and white blood cells), while the proportions of Actinobacteria and Firmicutes tended to be negatively correlated with these parameters. All patients received antibiotic prophylaxis (cefmetazole) as a single intravenous drip infusion on the days of surgery

and one day after surgery, which may be one of the causes of the microbiota changes. Considering the physiological functions of each bacterial group, Proteobacteria are normally present at low levels in a healthy gut environment but often overgrow in inflammatory states [33, 34], leading to opportunistic infections. Biagi et al. [35] showed positive correlations between opportunistic enterobacteria and some pro-inflammatory markers (IL-6 and IL-8). Contrarily, the genus *Bifidobacterium* is a bacterial group known to downregulate the pro-inflammatory response of the gut epithelium [36, 37]. These observations suggest a possible association between the balance of the microbiota and systemic inflammatory response of the patients.

On the other hand, the current study showed that the proportion of Actinobacteria positively correlated with the levels of erythrocytes, hemoglobin, albumin, and NK cell activity and that the proportion of Firmicutes positively correlated with the levels of lymphocytes, total protein, and albumin; all these parameter tended to be negatively correlated with the proportions of Proteobacteria and Bacteroidetes. As described above, the anti-inflammatory effects and the metabolites generated in the intestine by bifidobacteria, the main components of Actinobacteria, might have contributed to the improvement of the immune function, hematological, and nutritional parameters of these patients. Several studies have demonstrated the effects of administration of *B. longum* BB536 in maintaining balance and eliminating harmful bacteria [38–40]. Therefore, we think that probiotic ingestion contributed to the increased proportion of Actinobacteria in the microbiota, which might have also influenced the proportions of other components of the microbiota. Based on these findings, we conclude that maintaining the balance of the gut microbiota is important for maintaining host defenses and nutritional status, especially during recovery from major surgery.

This study has several limitations. We were unable to perform a placebo-controlled trial due to ethical issues in this hospital. Although the physicians who diagnosed infections were not directly involved in the randomization, we could not exclude the possibility of bias in the clinical observation of the infectious symptoms. However, administration of probiotics had objective effects on blood parameters and the composition of the microbiota. Another limitation is that the number of subject might have been insufficient to detect possible clinical significance, because of the low incidence of postoperative infection. We expected an incidence of 40% of postoperative infectious complications in the control

group, but it was much lower (approximately 31%). Therefore, future large-scale randomized controlled trial (RCT) studies are needed to confirm the health benefits of the ingestion of *B. longum* BB536 for patients with unbalanced health conditions.

In conclusion, this study shows the potential of the *B. longum* BB536 intervention in balancing the postoperative intestinal microbiota, attenuating systemic postoperative inflammatory responses, and improving recovery of hematological and nutritional conditions in patients undergoing colorectal surgery. These beneficial effects are likely to reduce the risk of postoperative infectious complications and to promote healthy recovery after colorectal resection. Our findings suggest that the administration of *B. longum* BB536 may represent an effective strategy to maintain a balance in the microbiota and promote healthy recovery in patients undergoing surgery.

#### ACKNOWLEDGEMENT

The authors thank Dr. Liong MT at School of Industrial Technology, Universiti Sains Malaysia, for her critical check of this manuscript.

#### REFERENCES

1. Food and Agriculture Organization of the United Nations and World Health Organization. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Available at: [http://www.fao.org/es/ESN/food/food\\_probio\\_en.stm](http://www.fao.org/es/ESN/food/food_probio_en.stm).
2. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. 2001. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. *Gastroenterology* 121: 580–591. [[Medline](#)] [[CrossRef](#)]
3. Macfarlane GT, Cummings JH. 2002. Probiotics, infection and immunity. *Curr Opin Infect Dis* 15: 501–506. [[Medline](#)] [[CrossRef](#)]
4. Rayes N, Seehofer D, Hansen S, Boucsein K, Müller AR, Serke S, Bengmark S, Neuhaus P. 2002. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. *Transplantation* 74: 123–127. [[Medline](#)] [[CrossRef](#)]
5. Kanazawa H, Nagino M, Kamiya S, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, Nimura Y. 2005. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. *Langenbecks Arch Surg* 390: 104–113. [[Medline](#)] [[CrossRef](#)]
6. Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, Nomoto K, Nimura Y. 2006. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. *Ann Surg* 244: 706–714. [[Medline](#)] [[CrossRef](#)]
7. Nomura T, Tsuchiya Y, Nashimoto A, Yabusaki H, Takii Y, Nakagawa S, Sato N, Kanbayashi C, Tanaka O. 2007. Probiotics reduce infectious complications after pancreaticoduodenectomy. *Hepatogastroenterology* 54: 661–663. [[Medline](#)]
8. Okazaki M, Matsukuma S, Suto R, Miyazaki K, Hidaka M, Matsuo M, Noshima S, Zempo N, Asahara T, Nomoto K. 2013. Perioperative synbiotic therapy in elderly patients undergoing gastroenterological surgery: a prospective, randomized control trial. *Nutrition* 29: 1224–1230. [[Medline](#)] [[CrossRef](#)]
9. Peitsidou K, Karantanos T, Theodoropoulos GE. 2012. Probiotics, prebiotics, synbiotics: is there enough evidence to support their use in colorectal cancer surgery? *Dig Surg* 29: 426–438. [[Medline](#)] [[CrossRef](#)]
10. He D, Wang HY, Feng JY, Zhang MM, Zhou Y, Wu XT. 2013. Use of pro-/synbiotics as prophylaxis in patients undergoing colorectal resection for cancer: a meta-analysis of randomized controlled trials. *Clin Res Hepatol Gastroenterol* 37: 406–415. [[Medline](#)] [[CrossRef](#)]
11. Jeppsson B, Mangell P, Thorlacius H. 2011. Use of probiotics as prophylaxis for postoperative infections. *Nutrients* 3: 604–612. [[Medline](#)] [[CrossRef](#)]
12. Xiao JZ. *Bifidobacterium longum* BB536. In: Lee KL, Salminen S (eds). 2009. *Hanbook of Probiotics and Prebiotics*, 2nd ed. John Wiley & Sons, New Jersey, pp. 488–491.
13. Akatsu H, Iwabuchi N, Xiao JZ, Matsuyama Z, Kurihara R, Okuda K, Yamamoto T, Maruyama M. 2013. Clinical effects of probiotic *Bifidobacterium longum* BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding. *JPEN J Parenter Enteral Nutr* 37: 631–640. [[Medline](#)] [[CrossRef](#)]
14. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Hospital Infection Control Practices Advisory Committee. 1999. Guideline for prevention of surgical site infection, 1999. *Infect Control Hosp Epidemiol* 20: 250–278, quiz 279–280. [[Medline](#)] [[CrossRef](#)]
15. Namba K, Hatano M, Yaeshima T, Takase M, Suzuki K. 2010. Effects of *Bifidobacterium longum* BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly. *Biosci Biotechnol Biochem* 74: 939–945. [[Medline](#)] [[CrossRef](#)]
16. Odamaki T, Xiao JZ, Iwabuchi N, Sakamoto M, Takahashi N, Kondo S, Miyaji K, Iwatsuki K, Togashi H, Enomoto T, Benno Y. 2007. Influence

- of *Bifidobacterium longum* BB536 intake on faecal microbiota in individuals with Japanese cedar pollinosis during the pollen season. *J Med Microbiol* 56: 1301–1308. [Medline] [CrossRef]
17. Aronesty E. 2013. Comparison of sequencing utility programs. *Open Bioinforma J* 7: 1–8. [CrossRef]
  18. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* 7: 335–336. [Medline] [CrossRef]
  19. Kuczynski J, Stombaugh J, Walters WA, González A, Caporaso JG, Knight R. 2011. Using QIIME to analyze 16S rRNA gene sequences from microbial communities. *Current Protocols in Bioinformatics Chapter 10: Unit 10.7*.
  20. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. 2011. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics* 27: 2194–2200. [Medline] [CrossRef]
  21. McDonald D, Price MN, Goodrich J, Nawrocki EP, DeSantis TZ, Probst A, Andersen GL, Knight R, Hugenholtz P. 2012. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. *ISME J* 6: 610–618. [Medline] [CrossRef]
  22. Liu Z, Qin H, Yang Z, Xia Y, Liu W, Yang J, Jiang Y, Zhang H, Yang Z, Wang Y, Zheng Q. 2011. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery—a double-blind study. *Aliment Pharmacol Ther* 33: 50–63. [Medline] [CrossRef]
  23. Zhang JW, Du P, Gao J, Yang BR, Fang WJ, Ying CM. 2012. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. *Am J Med Sci* 343: 199–205. [Medline] [CrossRef]
  24. Liu ZH, Huang MJ, Zhang XW, Wang L, Huang NQ, Peng H, Lan P, Peng JS, Yang Z, Xia Y, Liu WJ, Yang J, Qin HL, Wang JP. 2013. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. *Am J Clin Nutr* 97: 117–126. [Medline] [CrossRef]
  25. Xu Y, Teng F, Huang S, Lin Z, Yuan X, Zeng X, Yang F. 2014. Changes of saliva microbiota in nasopharyngeal carcinoma patients under chemoradiation therapy. *Arch Oral Biol* 59: 176–186. [Medline] [CrossRef]
  26. Fraunholz IB, Haberl A, Klauke S, Gute P, Rödel CM. 2014. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease. *Dis Colon Rectum* 57: 423–431. [Medline] [CrossRef]
  27. Tomosada Y, Villena J, Murata K, Chiba E, Shimazu T, Aso H, Iwabuchi N, Xiao JZ, Saito T, Kitazawa H. 2013. Immunoregulatory effect of bifidobacteria strains in porcine intestinal epithelial cells through modulation of ubiquitin-editing enzyme A20 expression. *PLoS ONE* 8: e59259. [Medline] [CrossRef]
  28. Parvaneh K, Jamaluddin R, Karimi G, Erfani R. 2014. Effect of probiotics supplementation on bone mineral content and bone mass density. *ScientificWorldJournal* 2014: 595962. [Medline] [CrossRef]
  29. Deguchi Y, Morishita T, Mutai M. 1985. Comparative studies on synthesis of water-soluble vitamins among human species of bifidobacteria. *Agric Biol Chern* 49: 13–19. [CrossRef]
  30. Sugahara H, Odamaki T, Hashikura N, Abe F, Xiao JZ. 2015. Differences in folate production by bifidobacteria of different origins. *Biosci Microbiota Food Health* 34: 87–93. [Medline] [CrossRef]
  31. Iyer R, Tomar SK. 2009. Folate: a functional food constituent. *J Food Sci* 74: R114–R122. [Medline] [CrossRef]
  32. LeBlanc JG, Laiño JE, del Valle MJ, Vannini V, van Sinderen D, Taranto MP, de Valdez GF, de Giori GS, Sesma F. 2011. B-group vitamin production by lactic acid bacteria—current knowledge and potential applications. *J Appl Microbiol* 111: 1297–1309. [Medline] [CrossRef]
  33. Pédrón T, Sansonetti P. 2008. Commensals, bacterial pathogens and intestinal inflammation: an intriguing ménage à trois. *Cell Host Microbe* 3: 344–347. [Medline] [CrossRef]
  34. Sansonetti PJ. 2011. To be or not to be a pathogen: that is the mucosally relevant question. *Mucosal Immunol* 4: 8–14. [Medline] [CrossRef]
  35. Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkila J, Monti D, Satokari R, Franceschi C, Brigidi P, De Vos W. 2010. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. *PLoS ONE* 5: e10667. [Medline] [CrossRef]
  36. Groeger D, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. 2013. *Bifidobacterium infantis* 35624 modulates host inflammatory processes beyond the gut. *Gut Microbes* 4: 325–339. [Medline] [CrossRef]
  37. Sagar S, Morgan ME, Chen S, Vos AP, Garssen J, van Bergenhenegouwen J, Boon L, Georgiou NA, Kraneveld AD, Folkerts G. 2014. *Bifidobacterium breve* and *Lactobacillus rhamnosus* treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma. *Respir Res* 15: 46. [Medline] [CrossRef]
  38. Ogata T, Takahashi S, Fukuwatari Y, Ishibashi N,

- Fujisawa T, Iino H. 1997. Effect of *Bifidobacterium longum* BB536 administration on the intestinal environment, defecation frequency and fecal characteristics of human volunteers. *Bioscience Microflora* 16: 53–58. [[CrossRef](#)]
39. Yaeshima T, Takahashi S, Matsumoto N, Ishibashi N, Hayasawa H, Iino H. 1997. Effect of yogurt containing *Bifidobacterium longum* BB536 on the intestinal environment, fecal characteristics and defecation frequency: a comparison with standard yogurt. *Bioscience Microflora* 16: 73–77. [[CrossRef](#)]
40. Odamaki T, Sugahara H, Yonezawa S, Yaeshima T, Iwatsuki K, Tanabe S, Tominaga T, Togashi H, Benno Y, Xiao JZ. 2012. Effect of the oral intake of yogurt containing *Bifidobacterium longum* BB536 on the cell numbers of enterotoxigenic *Bacteroides fragilis* in microbiota. *Anaerobe* 18: 14–18. [[Medline](#)] [[CrossRef](#)]